BridgeBio Pharma (BBIO)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of BridgeBio Pharma (BBIO)
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Key Insights
Critical company metrics and information
Share Price
$27.53Market Cap
$5.20 BillionTotal Outstanding Shares
188.99 Million SharesTotal Employees
556Dividend
No dividendIPO Date
June 27, 2019SIC Description
Pharmaceutical PreparationsHomepage
https://www.bridgebio.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities, Continuing | $270.00 Million |
Net Cash Flow | $-116.26 Million |
Net Cash Flow From Investing Activities, Continuing | $63.95 Million |
Net Cash Flow From Operating Activities, Continuing | $-450.22 Million |
Net Cash Flow From Operating Activities | $-450.22 Million |
Net Cash Flow From Financing Activities | $270.00 Million |
Net Cash Flow, Continuing | $-116.26 Million |
Net Cash Flow From Investing Activities | $63.95 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Operating Expenses | $7.57 Million |
Operating Expenses | $759.74 Million |
Operating Income/Loss | $-544.36 Million |
Nonoperating Income/Loss | $98.08 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $-7.43 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-438.86 Million |
Basic Average Shares | $188.85 Million |
Benefits Costs and Expenses | $664.05 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Income/Loss From Continuing Operations After Tax | $-446.29 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Revenues | $217.76 Million |
Gross Profit | $215.37 Million |
Diluted Average Shares | $188.85 Million |
Research and Development | $506.34 Million |
Costs And Expenses | $762.13 Million |
Income/Loss From Continuing Operations Before Tax | $-446.29 Million |
Diluted Earnings Per Share | $2.42 |
Net Income/Loss Attributable To Parent | $-438.86 Million |
Cost Of Revenue | $2.39 Million |
Net Income/Loss | $-446.29 Million |
Selling, General, and Administrative Expenses | $241.73 Million |
Basic Earnings Per Share | $2.42 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Liabilities | $1.74 Billion |
Fixed Assets | $8.70 Million |
Intangible Assets | $24.52 Million |
Current Assets | $444.58 Million |
Liabilities And Equity | $664.98 Million |
Other Current Liabilities | $82.31 Million |
Liabilities | $1.88 Billion |
Equity | $-1.22 Billion |
Current Liabilities | $139.22 Million |
Equity Attributable To Noncontrolling Interest | $10.88 Million |
Equity Attributable To Parent | $-1.23 Billion |
Wages | $43.54 Million |
Other Non-current Assets | $187.17 Million |
Noncurrent Assets | $220.40 Million |
Assets | $664.98 Million |
Accounts Payable | $13.36 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.